IRIS
ARMUZZI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.010
EU - Europa 1.672
AS - Asia 395
AF - Africa 72
SA - Sud America 2
OC - Oceania 1
Totale 8.152
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.994
FI - Finlandia 528
IE - Irlanda 409
FR - Francia 209
CN - Cina 199
DE - Germania 150
NL - Olanda 119
IN - India 113
GB - Regno Unito 74
NG - Nigeria 68
IT - Italia 44
SE - Svezia 42
RU - Federazione Russa 38
BE - Belgio 29
IR - Iran 21
CA - Canada 16
HK - Hong Kong 14
IL - Israele 11
SG - Singapore 10
TR - Turchia 10
JP - Giappone 9
RO - Romania 5
EG - Egitto 4
ES - Italia 4
BG - Bulgaria 3
PL - Polonia 3
AE - Emirati Arabi Uniti 2
AT - Austria 2
EE - Estonia 2
PH - Filippine 2
TW - Taiwan 2
UA - Ucraina 2
AR - Argentina 1
AU - Australia 1
BN - Brunei Darussalam 1
BR - Brasile 1
CH - Svizzera 1
DK - Danimarca 1
IS - Islanda 1
LU - Lussemburgo 1
MK - Macedonia 1
NO - Norvegia 1
PT - Portogallo 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
VN - Vietnam 1
Totale 8.152
Salva come PNG Salva come JPEG
Città #
Chandler 1.802
Helsinki 528
Dublin 409
Ashburn 395
Lawrence 389
Princeton 389
Boardman 354
New York 213
Paris 205
Shanghai 192
Wilmington 177
Amsterdam 119
Pune 110
London 69
Benin City 67
San Mateo 63
Ann Arbor 49
Moscow 35
Phoenix 30
Brussels 28
Leawood 28
Fairfield 19
Woodbridge 18
Frankfurt am Main 16
Toronto 13
Oshnaviyeh 12
Falkenstein 11
Berlin 9
Milan 9
Kocaeli 8
Hanover 6
Hong Kong 6
Norwalk 5
Santa Clara 5
Campobasso 4
Seattle 4
Singapore 4
Tokyo 4
Atlanta 3
Beijing 3
Cambridge 3
Hirakata 3
Houston 3
Madrid 3
Miami 3
Rome 3
Sassari 3
Sofia 3
Tel Aviv 3
Cairo 2
Cinisello Balsamo 2
Collegeville 2
Genoa 2
Hadera 2
Istanbul 2
Los Angeles 2
Montichiari 2
Ottawa 2
Qingdao 2
Redwood City 2
Sale Marasino 2
St Petersburg 2
Stockholm 2
Tallinn 2
Toulouse 2
Turin 2
Vienna 2
Warsaw 2
Assiut 1
Augusta 1
Bandar Seri Begawan 1
Belgrade 1
Bitola 1
Buenos Aires 1
Buffalo 1
Cary 1
Chicago 1
Clearwater 1
Copenhagen 1
Craiova 1
Dalsjoefors 1
Delhi 1
Dubai 1
Hangzhou 1
Harlow 1
Henderson 1
Ho Chi Minh City 1
Jaipur 1
Keflavik 1
Kemerovo 1
Kyiv 1
La Canada Flintridge 1
Lagos 1
Lancenigo-Villorba 1
Las Vegas 1
Lisbon 1
Livorno 1
Luxembourg 1
Manchester 1
Mesa 1
Totale 5.907
Salva come PNG Salva come JPEG
Nome #
A liophylized and inactivated colture of Lactobacillus acidophilus increases Helicobacter pylori eradication rate 58
Adalimumab in active ulcerative colitis: A "real-life" observational study 53
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 50
Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease 49
13C-Breath Tests in the study of microsomal liver function 47
13C-breath tests in the study of mitochondrial liver function 47
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting 44
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial 43
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management 43
Long-term Combination Therapy with Infliximab Plus Azathioprine Predicts Sustained Steroid-free Clinical Benefit in Steroid-dependent Ulcerative Colitis 42
Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study 42
Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease 41
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission 40
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment 39
FOXP3(+) T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNF alpha Agents 39
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 38
Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study 37
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. Sandborn WJ, Feagan BG, Loftus EV Jr, Peyrin-Biroulet L, Van Assche G, D'Haens G, Schreiber S, Colombel JF, Lewis JD, Ghosh S, Armuzzi A, Scherl E, Herfarth H, Vitale L, Mohamed MF, Othman AA, Zhou Q, Huang B, Thakkar RB, Pangan AL, Lacerda AP, Panes J 36
H-pylori poliantibiotic resistant strains in dyspeptic patients not eradicated by two consecutive triple eradication regimens 36
A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery 36
Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 36
ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment 36
The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases 35
Role of helicobacter pylori in gastroesophageal reflux disease 35
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar 35
H-pylori gastric infection and rheumatic diseases 34
A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates 34
Long-term scheduled therapy with infliximab in inflammatory bowel disease 34
Difference in treatment outcomes between clinical trials and "real-life" clinical practice: ustekinumab in ulcerative colitis 34
HELICOBACTER-PYLORI GASTRITIS WITH CYTOTOXIN ASSOCIATED PROTEIN ANTIBODIES (CAGA) - A COMPUTER-AIDED EVALUATION OF INFLAMMATORY CELL INFILTRATION IN THE LAMINA PROPRIA, ATROPHIC GASTRITIS AND ACQUIRED MALT 33
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders 33
A transition clinic model for inflammatory bowel disease between two tertiary care centers: outcomes and predictive factors 33
Disease patterns in late-onset ulcerative colitis: Results from the " IG-IBD ""AGED study""" 33
The intercellular adhesion molecule-1 polymorphisms in IBD 32
3-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure H-pylori infection 32
Helicobacter pylori eradication ameliorates migraine: An extended follow up study 32
Anti-CagA antibodies are associated with atrophic gastritis in a population at high gastric cancer risk: a morphometric study by computerized image analysis 32
Adherence to international guidelines for the management of Helicobacter pylori infection among gastroenterologists and gastroenterology fellows in Italy: A Survey of the Italian Federation of Digestive Diseases - FISMAD 32
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 32
Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease 32
Antibiotic resistance of H-pylori strains obtained by dyspeptic patients not eradicated by two consecutive eradication regimens 31
Infliximab in Steroid-Dependent Ulcerative Colitis 31
Acute pancreatitis and parathyroid carcinoma: a case report and literature review 31
Efficacy of a multistep strategy for Helicobacter pylori eradication 31
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study 31
C-13-methionine breath tests for mitochondrial liver function assessment 30
Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future 30
Fecal calprotection in first-degree relatives of patients with ulcerative colitis 30
Aminopyrine and methacetin 13C-breath tests to assess hepatic function in HCV-related chronic liver disease 30
Long-Term Scheduled Therapy with Infliximab in Inflammatory Bowel Disease 30
Hepatic mitochondrial beta-oxidation in patients with Nonalcoholic-Steatohepatitis (NASH) assessed by 13C-octanoate breath test 30
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results 30
Dual Targeted Therapy in Patient With Extensive Crohn's Disease: Different Response at Distinct Location 30
COMPLEX PERIANAL FISTULIZING CROHN'S DISEASE: LONG-TERM EFFICACY OF COMBINED SETON PLACEMENT AND ANTI TNF-ALPHA AGENTS ALONE OR ASSOCIATED WITH IMMUNOSUPPRESSANTS 29
Helicobacter pylori-related diseases 29
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 29
Reply to Dr. Kotze's and Dr. Yamamoto's letter 29
Complex Perianal Crohn's Disease: Effectiveness of Combined Seton Placement and Anti-TNF Alpha Agents in Monotherapy or in Association With Immunosuppressants 29
Adalimumab in the treatment of immune-mediated diseases 29
Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients 29
anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab 29
C-13 urea breath test for predicting resistance to therapy in Helicobacter pylori infection 29
Activity of Crohn's disease and small bowel contract-enhanced ultrasound findings 29
Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign 29
Young GI angle: Should I go abroad? 28
INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS ON ANTI TNF-ALPHA THERAPY: RESPONSE TO THE INFLUENZA A/H1N1 VACCINE 28
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study 28
Diet and Nutrients in Gastrointestinal Chronic Diseases 28
Advances in extracorporeal detoxification by MARS dialysis in patients with liver failure 28
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 28
Gender affects 13C-ketoisocaproic breath test for liver mitochondrial function 28
Objective comparison of vedolizumab and ustekinumab effectiveness in Crohn's disease patients failure to TNF-alpha inhibitors 28
Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery? 28
Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease 28
Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study 28
Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use 28
Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study 27
Haplotypic analysis of heat shock protein 70 (HSP70) single nucleotide polymorphisms (SNPs) in susceptibility and phenotype of inflammatory bowel disease (IBD) 27
New developments in biologics therapy: what about from the medical point of view? 27
Editorial: withdrawal of anti TNF-alpha - are we ready for biological therapy cycling? 27
Hepatic mitochondrial function assessment through C-13-methionine and C-13-sodium octanoate breath tests 27
Levofloxacin based regimens for the eradication of Helicobacter pylori 27
Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management 27
Usefulness of C-13-methionine breath test as a non-invasive and dynamic tool to evaluate residual hepatic mitochondrial function 27
The management of inflammatory bowel diseases in the era of COVID-19 pandemic: When "non-urgent" does not mean "deferrable" 27
Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study 27
C-13-methacetin breath test in patients with nonalcoholic steatohepatitis 27
Ulcerative Colitis Narrative Global Survey Findings: Communication Gaps and Agreements Between Patients and Physicians 27
Update on the management of inflammatory bowel disease: specific role of adalimumab 27
DISAPPEARANCE OF GASTRIC ACQUIRED MALT AND REGRESSION OF LOW-GRADE B-CLL GASTRIC LYMPHOMA BY MEAN ANTI-H-PYLORI TREATMENT 27
A novel pathogenic role for microvasculature in inflammatory bowel disease 27
Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open 27
Incidence and symptoms related to Helicobacter pylori infection in dyspeptic patients 26
Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study 26
Gender affects C-13-ketoisocaproic acid breath test 26
Importance of changes in epithelial cell turnover during Helicobacter pylori infection in gastric carcinogenesis 26
New concepts concerning management of Helicobacter pylori infection: 2 years after the Maastricht Consensus Report 26
COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Italian IBD Patients' Association 26
Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials 26
Oxygen free radical production in rat liver: Effect of different doses of ethanol on anoxia-reperfusion injury 26
Totale 3.219
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.798
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.798
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20208 0 0 0 0 0 0 0 0 0 0 0 8
2020/2021320 2 3 1 4 0 106 40 21 71 41 1 30
2021/2022223 6 2 11 42 3 0 7 24 18 18 49 43
2022/20235.204 840 55 422 571 430 547 7 531 960 454 333 54
2023/20242.479 219 317 780 260 112 383 184 108 26 90 0 0
Totale 8.234